ERBB2 and neoplasm: Although the concentration of tribody [(HER2)2xCD16] was 10-fold lower than that of trastuzumab, the tribody significantly and more potently enhanced the PBL-mediated lysis of HER2-expressing tumor cells (Figure 4A).